23:52 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Cell culture studies suggest inhibiting L selectin shedding could help treat latent HIV infection. In L selectin-expressing CD4+ T cells exposed to HIV-1, a tool compound matrix metalloproteinase 1 (MMP1) inhibitor that blocks...
20:12 , Sep 26, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest inhibiting ADAM10 with INCB7839 could help treat brain cancer. In a mouse model of high-grade glioma, knockout of NLGN3 -- which is activated by ADAM10-mediated cleavage from synaptic membranes --...
16:25 , Sep 20, 2017 |  BC Extra  |  Preclinical News

Inhibiting ADAM10 could help treat brain cancer

In a paper published in Nature, researchers at Stanford University and colleagues showed that glioma growth is dependent on neuroligin 3 (NLGN3), and that inhibiting ADAM metallopeptidase domain 10 (ADAM10) reduced NLGN3 shedding from neurons...
21:45 , Jul 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
07:00 , Jun 12, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer ADAM10; ADAM17 In vitro studies suggest inhibiting ADAM10 and ADAM17 could help stimulate an NK cell...
07:00 , Apr 18, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Head and neck cancer ADAM17; microRNA-145 (miR-145); SRY (sex determining region Y)-box 9 (SOX9); IL-6 Mouse and...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

INCB7839: Development discontinued

Incyte disclosed in its 3Q11 earnings that it discontinued development of INCB7839 to treat metastatic breast cancer. Incyte said the decision was based on an analysis of tissue samples from >300 breast cancer patients showing...
07:00 , Mar 31, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Inflammation; cancer ADAM17 In vitro studies identified an anti-ADAM17 antibody that could...
08:00 , Jan 27, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer HER2 (ERBB2; neu); ADAM17 In vitro and mouse studies suggest that pan-HER and ADAM17 inhibitors...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Clinical News

INCB7839: Additional Phase I/II data

Incyte reported additional data from the ongoing, open-label, dose-escalation Phase I/II INCB7839-202 trial in patients with metastatic breast cancer positive for epidermal growth factor (EGF) receptor 2 ( HER2, ErbB2, neu). In the...